ME02808B - Makrociklička jedinjenja kao inhibitori TRK kinaze - Google Patents
Makrociklička jedinjenja kao inhibitori TRK kinazeInfo
- Publication number
- ME02808B ME02808B MEP-2017-161A MEP16117A ME02808B ME 02808 B ME02808 B ME 02808B ME P16117 A MEP16117 A ME P16117A ME 02808 B ME02808 B ME 02808B
- Authority
- ME
- Montenegro
- Prior art keywords
- fluoro
- hexaazapentacyclo
- heptaen
- hexaene
- dione
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- GILAGZOPOKXBMB-CQSZACIVSA-N (6R)-9-fluoro-14-oxa-2,11,18,19,22-pentazapentacyclo[14.5.2.17,11.02,6.019,23]tetracosa-1(22),7,9,16(23),17,20-hexaene-15,24-dione Chemical compound C([C@@H]12)CCN1C(=NC1=3)C=CN1N=CC=3C(=O)OCCN1C=C(F)C=C2C1=O GILAGZOPOKXBMB-CQSZACIVSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- UHWGZELMUUQSBI-IUODEOHRSA-N (6R,13R)-9-fluoro-13-hydroxy-2,11,15,19,20,23-hexazapentacyclo[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione Chemical compound O=C1C([C@H]2CCCN2C(=N2)C=C3)=CC(F)=CN1C[C@H](O)CNC(=O)C1=C2N3N=C1 UHWGZELMUUQSBI-IUODEOHRSA-N 0.000 claims 1
- JPFKIYMOMOJXMF-MRXNPFEDSA-N (6r)-9-fluoro-13,13-dimethyl-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione Chemical compound O=C1C([C@H]2CCCN2C(=N2)C=C3)=CC(F)=CN1CC(C)(C)CNC(=O)C1=C2N3N=C1 JPFKIYMOMOJXMF-MRXNPFEDSA-N 0.000 claims 1
- MNBWDIGNEWSBTG-OAHLLOKOSA-N (6r)-9-fluoro-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione Chemical compound C([C@@H]12)CCN1C(=NC1=3)C=CN1N=CC=3C(=O)NCCCN1C=C(F)C=C2C1=O MNBWDIGNEWSBTG-OAHLLOKOSA-N 0.000 claims 1
- CGHFNIXGLSTXOA-IUODEOHRSA-N (6r,13r)-9,13-difluoro-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione Chemical compound O=C1C([C@H]2CCCN2C(=N2)C=C3)=CC(F)=CN1C[C@H](F)CNC(=O)C1=C2N3N=C1 CGHFNIXGLSTXOA-IUODEOHRSA-N 0.000 claims 1
- ZQTNTFAUQJEQHU-MLGOLLRUSA-N (6r,13r)-9-fluoro-13-methyl-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione Chemical compound O=C1C([C@H]2CCCN2C(=N2)C=C3)=CC(F)=CN1C[C@H](C)CNC(=O)C1=C2N3N=C1 ZQTNTFAUQJEQHU-MLGOLLRUSA-N 0.000 claims 1
- UHWGZELMUUQSBI-SWLSCSKDSA-N (6r,13s)-9-fluoro-13-hydroxy-2,11,15,19,20,23-hexaazapentacyclo-[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione Chemical compound O=C1C([C@H]2CCCN2C(=N2)C=C3)=CC(F)=CN1C[C@@H](O)CNC(=O)C1=C2N3N=C1 UHWGZELMUUQSBI-SWLSCSKDSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical group N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (17)
1.Jedinjenje, naznačeno time, što ima Formulu Iili neka njegova farmaceutski prihvatljiva so, pri čemu:prsten A je izabran iz prstena A-1 i A-2 sa sledećim strukturama:gde naborana linija označena sa 1 pokazuje tačku spajanja prsten A na prsten B, a naborana linija označena sa 2 pokazuje tačku spajanja prstena A na W;X je N ili CH;Y je H ili F;R1 je H, (1-3C)alkoksi ili halogen;pri čemu kada prsten B je B-1,gde naborana linija označena sa 3 pokazuje tačku spajanja na prsten A, a naborana linija označena sa 4 pokazuje tačku spajanja na pirazolo[1,5-a]pirimidinski prsten iz Formule I;W je O, NH ili CH2, pri čemu kada prsten A je A-2, tada W je CH2;m je 0, 1 ili 2;D je ugljenik, R2 i R2a su nezavisno H, F, (1-3 C)alkil ili OH (pod uslovom da R2 i R2a nisu oba OH), a R3 i R3a su nezavisno H, (1-3 C)alkil ili hidroksi(1-3 C)alkil,Z je *-NR4aC(=O)-, pri čemu zvezda pokazuje tačku spajanja Z na ugljenik koji nosi R3;R4a je H, (1-6C)alkil, fluoro(1-6C)alkil, difluoro(1-6C)alkil, trifluoro(1-6C)alkil, hidroksi(1-6C alkil) ili dihidroksi(2-6C alkil); aR5 i R6 su nezavisno H, halogen, OH, (1-6C)alkil ili hidroksi(1-6C)alkil.
2.Jedinjenje u skladu sa zahtevom 1, naznačeno time, što prsten A je prsten A-1 sa strukturom:
3.Jedinjenje u skladu sa zahtevom 1, naznačeno time, što prsten A je prsten A-2 sa strukturom:
4.Jedinjenje u skladu sa bilo kojim od zahteva 1-3, naznačeno time, što Y je F.
5.Jedinjenje u skladu sa bilo kojim od zahteva 1-4, naznačeno time, što R1 je H.
6.Jedinjenje u skladu sa bilo kojim od zahteva 1-5, naznačeno time, što R4a je vodonik.
7.Jedinjenje u skladu sa bilo kojim od zahteva 1-6, naznačeno time, što R2 i R2a su atomi vodonika.
8.Jedinjenje u skladu sa bilo kojim od zahteva 1-7, naznačeno time, što W je CH2.
9.Jedinjenje u skladu sa bilo kojim od zahteva 1-8, naznačeno time, što m je 0.
10.Jedinjenje u skladu sa bilo kojim od zahteva 1-8, naznačeno time, što m je 1.
11.Jedinjenje iz zahteva 1, naznačeno time, što je izabrano iz sledećih jedinjenja: (6R)-9-fluoro-2,11,15,19,20,23-heksaazapentaciklo[15.5.2.17,110.2,6.020,24]pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R)-9-fluoro-13-oksa-2,11,17,21,22,25-heksaazapentaciklo[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9-fluoro-15-hidroksi-13-oksa-2,11,17,21,22,25-heksaazapentaciklo[17.5.2.02,6.07,120.22,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R,13S)-9-fluoro-13-hidroksi-2,11,15,19,20,23-heksaazapentaciklo-[15.5.2.17,11.02,6.020,24]pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R,15R)-9-fluoro-15-hidroksi-13-oksa-2,11,17,21,22,25-heksaazapentaciklo-[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R,13R)-9-fluoro-13-hidroksi-2,11,15,19,20,23-heksaazapentaciklo-[15.5.2.17,11.02,6.020,24]pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R)-9-fluoro-13-oksa-2,11,16,20,21,24-heksaazapentaciklo[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; (6R)-9-fluoro-13-oksa-2,11,18,22,23,26-heksaazapentaciklo[18.5.2.02,6.07,12.023,27]heptakosa-1(26),7,9,11,20(27),21,24-heptaen-19-on; (6R)-9-fluoro-2,11,16,20,21,24-heksaazapentaciklo[16.5.2.17,11.02,6.021,25]heksakosa-1(24),7,9,18(25),19,22-heksaen-17,26-dion; (6R)-9-fluoro-2,11,13,16,20,21,24-heptaazapentaciklo[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; (6R)-9-fluoro-2,11,13,17,21,22,25-heptaazapentaciklo[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9-fluoro-14-oksa-2,11,18,19,22-pentaazapentaciklo[14.5.2.17,11.02,6.019,23]tetracosa-1(22),7,9,16(23),17,20-heksaen-15,24-dion; (6R,13R)-9,13-difluoro-2,11,15,19,20,23-heksaazapentaciklo[15.5.2.17,11.02,6.020,24]pentakosa-1 (23), 7,9,17(24),18,21-heksaen-16,25-dion; (6R)-9-fluoro-17-metil-13-oksa-2,11,17,21,22,25-heksaazapentaciklo[17.5.2.02,6.07,12.022,26]-heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9,15,15-trifluoro-13-oksa-2,11,17,21,22,25-heksaazapentaciklo-[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9-fluoro-2,11,16,20,21,24-heksaazapentaciklo[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; (6R)-9-fluoro-15-metil-2,11,16,20,21,24-heksaazapentaciklo-[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; (6R,13R)-9-fluoro-13-metil-2,11,15,19,20,23-heksaazapentaciklo-[15.5.2.17,11.02,6.020,24pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R,13S)-9-fluoro-13-metil-2,11,15,19,20,23-heksaazapentaciklo-[15.5.2.17,11.02,6.020,24]pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R)-9-fluoro-15,15-dimetil-13-oksa-2,11,17,21,22,25-heksaazapentaciklo-[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9-fluoro-15,15-dimetil-2,11,16,20,21,24-heksaazapentaciklo-[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; i (6R)-9-fluoro-13,13-dimetil-2,11,15,19,20,23-heksaazapentaciklo[15.5.2.17,11.02,6.020,24]-pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; ili neka njegova farmaceutski prihvatljiva so.
12.Jedinjenje iz zahteva 1, naznačeno time, što je izabrano iz sledećih jedinjenja: (6R)-9-fluoro-13-oksa-2,11,17,21,22,25-heksaazapentaciklo[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9-fluoro-15-hidroksi-13-oksa-2,11,17,21,22,25-heksaazapentaciklo[17.5.2.02.6.07,12.022,26]-heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R,15R)-9-fluoro-15-hidroksi-13-oksa-2,11,17,21,22,25-heksaazapentaciklo-[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9-fluoro-13-oksa-2,11,16,20,21,24-heksaazapentaciklo[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; (6R)-9-fluoro-13-oksa-2,11,18,22,23,26-heksaazapentaciklo[18.5.2.02,6.07,12.023,27]heptakosa-1(26),7,9,11,20(27),21,24-heptaen-19-on; (6R)-9-fluoro-2,11,13,16,20,21,24-heptaazapentaciklo[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; (6R)-9-fluoro-2,11,13,17,21,22,25-heptaazapentaciklo[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9-fluoro-17-metil-13-oksa-2,11,17,21,22,25-heksaazapentaciklo[17.5.2.02,6.07,12.022,26]-heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9,15,15-trifluoro-13-oksa-2,11,17,21,22,25-heksaazapentaciklo-[17.5.2.02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; (6R)-9-fluoro-2,11,16,20,21-,24-heksaazapentaciklo[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; (6R)-9-fluoro-15-metil-2,11,16,20,21,24-heksaazapentaciklo-[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; (6R)-9-fluoro-15,15-dimetil-13-oksa-2,11,17,21,22,25-heksaazapentaciklo-[17.5.2 .02,6.07,12.022,26]heksakosa-1(25),7,9,11,19(26),20,23-heptaen-18-on; i (6R)-9-fluoro-15,15-dimetil-2,11,16,20,21,24-heksaazapentaciklo-[16.5.2.02,6.07,12.021,25]pentakosa-1(24),7,9,11,18(25),19,22-heptaen-17-on; ili neka njegova farmaceutski prihvatljiva so.
13.Jedinjenje iz zahteva 1, naznačeno time, što je izabrano iz sledećih jedinjenja: (6R)-9-fluoro-2,11,15,19,20,23-heksaazapentaciklo[15.5.2.17,11.02,6.020,24]pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R,13S)-9-fluoro-13-hidroksi-2,11,15,19,20,23-heksaazapentaciklo-[15.5.2.17,11.02,6.020,24]-pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R,13R)-9-fluoro-13-hidroksi-2,11,15,19,20,23-heksaazapentaciklo-[15.5.2.17,11.02,6.020,24]-pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R)-9-fluoro-2,11,16,20,21,24-heksaazapentaciklo[16.5.2.17,11.02,6.021,25]heksakosa-1(24),7,9,18(25),19,22-heksaen-17,26-dion; (6R)-9-fluoro-14-oksa-2,11,18,19,22-pentaazapentaciklo[14.5.2.17,11.02,6.019,23]tetracosa-1(22),7,9, 16(23),17,20-heksaen-15,24-dion; (6R,13R)-9,13-difluoro-2,11,15,19,20,23-heksaazapentaciklo[15.5.2.17,11.02,6.020,24]pentakosa-1(23), 7,9,17(24),18,21-heksaen-16,25-dion; (6R,13R)-9-fluoro-13-metil-2,11,15,19,20,23-heksaazapentaciklo-[15.5.2.17,11.02,6.020,24]pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; (6R,13,S)-9-fluoro-13-metil-2,11,15,19,20,23-heksaazapentaciklo-[15.5.2.17,11.02,6.020,24]pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; i (6R)-9-fluoro-13,13-dimetil-2,11,15,19,20,23-heksaazapentaciklo[15.5.2.17,11.02,6.020,24]pentakosa-1(23),7,9,17(24),18,21-heksaen-16,25-dion; ili neka njegova farmaceutski prihvatljiva so.
14.Farmaceutska kompozicija, naznačena time, što sadrži jedinjenje sa Formulom I kao šta je definisano u bilo kojem od zahteva od 1 do 13, ili neku njegovu farmaceutski prihvatljivu so, i neki farmaceutski prihvatljivi razređivač ili nosilac.
15.Jedinjenje sa Formula I, kao šta je definisano u bilo kojem od zahteva od 1 do 12, ili neka njegova farmaceutski prihvatljiva so, naznačeno time, što se upotrebljava u tretmanu boli, raka, zapaljenja, neurodegenerativnih bolesti ili infekcija sa Trypanosoma cruzi.
16.Jedinjenje za primenu iz zahteva 15, naznačeno time, što se upotrebljava u tretmanu raka.
17. Jedinjenje za primenu iz zahteva 16, naznačeno time, što pomenuti je rak izabran iz grupe koja obuhvata: neuroblastom, rak jajnika, kolorektalni rak, melanom, rak glave i vrata, karcinom želuca, karcinom pluća, rak dojke, glioblastom, meduloblastom, sekretorni rak dojke, rak pljuvačne žlezde, papilarni karcinom štitaste žlezde, mijeloidnu leukemiju odraslih, rak pankreasa, i rak prostate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34676710P | 2010-05-20 | 2010-05-20 | |
| US201061426716P | 2010-12-23 | 2010-12-23 | |
| EP15150036.0A EP2918588B1 (en) | 2010-05-20 | 2011-05-13 | Macrocyclic compounds as TRK kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02808B true ME02808B (me) | 2018-01-20 |
Family
ID=55700963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-161A ME02808B (me) | 2010-05-20 | 2011-05-13 | Makrociklička jedinjenja kao inhibitori TRK kinaze |
Country Status (4)
| Country | Link |
|---|---|
| ME (1) | ME02808B (me) |
| NZ (1) | NZ703512A (me) |
| RS (1) | RS56275B1 (me) |
| UA (1) | UA110701C2 (me) |
-
2011
- 2011-05-13 NZ NZ703512A patent/NZ703512A/en not_active IP Right Cessation
- 2011-05-13 ME MEP-2017-161A patent/ME02808B/me unknown
- 2011-05-13 RS RS20170745A patent/RS56275B1/sr unknown
- 2011-05-13 UA UAA201214588A patent/UA110701C2/uk unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS56275B1 (sr) | 2017-11-30 |
| NZ703512A (en) | 2016-08-26 |
| UA110701C2 (uk) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171140T1 (hr) | Makrociklički spojevi kao inhibitori trk kinaze | |
| RU2019132666A (ru) | Макроциклические соединения в качестве ингибиторов киназы ros1 | |
| HRP20210871T1 (hr) | Piridopirimdinonski inhibitori cdk2/4/6 | |
| HRP20211927T1 (hr) | Derivati spojenih pentacikličnih imidazola kao modulatori aktivnosti tnf | |
| GEP201706774B (en) | Heterocyclyl compounds | |
| MX2013007148A (es) | 2-arilimidazo[1,2-b]piridazina, 2-fenilimidazo[1,2-a]pirimidina, y derivados de 2-fenilimidazo[1.2-a]pirazina. | |
| FI3805222T3 (fi) | 7-bentsyyli-4-(2-metyylibentsyyli)-2,4,6,7,8,9-heksahydroimidatso[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onijohdannaisia, niiden suoloja ja niiden käyttö hoidossa | |
| PH12017502171B1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| ME02394B (me) | Pirazolohinolinski derivati kao inhibitori pde9 | |
| EA201300620A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK | |
| NZ605292A (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| CA2875877C (en) | Syk inhibitors | |
| RU2008141239A (ru) | Соединения тетрагидропиридотиенопиримидина и способы их применения | |
| ES2721018T3 (es) | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 | |
| EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
| HRP20190814T1 (hr) | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci uporabe | |
| HRP20220628T1 (hr) | Postupci i međuprodukti za pripremu lijeka | |
| CL2012000042A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto. | |
| HRP20180444T1 (hr) | 9-aminometil-supstituirani tetraciklinski spojevi | |
| ME02107B (me) | Heteroaril jedinjenja kao ligandi 5-ht4 receptora | |
| NZ629230A (en) | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one | |
| JP2016517877A5 (me) | ||
| BR112019008263A2 (pt) | formulação lipossomal para uso no tratamento de câncer | |
| HRP20210095T1 (hr) | Novi derivati amino-imidazopiridina kao inhibitori janus kinaze i njihova farmaceutska upotreba | |
| ME02351B (me) | Derivati 2 -oxo- 1-imidazolidinil imidazotiadiazol |